The goal of this clinical research study is to find the highest tolerable dose of the
combination of ixazomib and erlotinib that can be given to patients with advanced solid
tumors. The safety of these drugs will also be studied.
This is an investigational study. Erlotinib is FDA approved and commercially available to
treat non-small cell lung cancer, but its use in advanced solid cancer is considered
investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs
are designed to work.
Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.